Evidence map›Paper›PMID 33029761›Full record

ReviewBiological trace element research2021

Metal Nanoparticles: a Promising Treatment for Viral and Arboviral Infections.

Kaminee Maduray, Raveen Parboosing

Open access · bronzeAbstract readReview
In one paragraph

Review in Biological trace element research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 112 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Research progress of mosquito-borne virus mRNA vaccines.Molecular therapy. Methods & clinical development · 2025
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Biogenic metallic nanoparticles: from green synthesis to clinical translation.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  16. Article
  17. Insight into Antiviral Activity of Ag/TiOInternational journal of nanomedicine · 2024
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Kaminee MadurayDepartment of Virology, University of KwaZulu-Natal/National Health Laboratory Service, Durban, South Africa. madurayk@yahoo.com.ORCID https://orcid.org/0000-0002-9335-4056
Raveen ParboosingDepartment of Virology, University of KwaZulu-Natal/National Health Laboratory Service, Durban, South Africa.
National Health Laboratory Service · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Globally, viral diseases continue to pose a significant threat to public health. Recent outbreaks, such as influenza, coronavirus, Ebola, and dengue, have emphasized the urgent need for new antiviral therapeutics. Considerable efforts have focused on developing metal nanoparticles for the treatment of several pathogenic viruses. As a result of these efforts, metal nanoparticles are demonstrating promising antiviral activity against pathogenic surrogates and clinical isolates. This review summarizes the application of metal nanoparticles for the treatment of viral infections. It provides information on synthesis methods, size-related properties, nano-bio-interaction, and immunological effects of metal nanoparticles. This article also addresses critical criteria and considerations for developing clinically translatable nanosized metal particles to treat viral diseases.

Indexed as

Metal NanoparticlesAntiviral AgentsMetalsAntiviral AgentsMetalsArbovirusMetal nanoparticleNanotechnologyNanotherapeuticsTreatmentVirus

Identifiers

PMID33029761
PMCPMC7540915
OpenAlexW3092400398

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.